Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 15/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 12/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lcl-161 SCHEMBL1275369 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL21064744 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL19164873 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL1275371 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL18663754 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL1495180 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL3688581 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975497 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975269 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975195 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464644-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | Novartis AG (CH) | 2012-06-20 | — | — | EP | claimed |
| WO-2011018474-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | claimed |
| US-12252535-B2 | Antibody molecules to LAG-3 and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | BioAlta, LLC | 2024-10-17 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230218669-A1 | AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES | FRED HUTCHINSON CANCER CENTER (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2022097060-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | WO | disclosed |
| EP-3642240-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018237173-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| US-20140024687-A1 | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists | CONWAY COLLEEN ANN (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2464644-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464347-A1 | COMBINATIONS OF VASCULAR DISRUPTING AGENTS WITH INHIBITOR OF APOPTOSIS PROTEINS ANTAGONISTS | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018474-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019782-A1 | COMBINATIONS OF VASCULAR DISRUPTING AGENTS WITH INHIBITOR OF APOPTOSIS PROTEINS ANTAGONISTS | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2008109057-A1 | ORGANIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | XIAP 1498/4885RIPK2 2685/4885ESR1 2429/4885 |
| US-20230218669-A1 | AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES | CD47, BAD, CD74 | XIAP 56/4885RIPK2 686/4885ESR1 1319/4885 |
| US-12252535-B2 | Antibody molecules to LAG-3 and uses thereof | CD274, PDCD1LG2, HAVCR2 | XIAP 626/4885RIPK2 2442/4885ESR1 2915/4885 |
| US-20140024687-A1 | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists | BIRC5, API5, BIRC3 | XIAP 4/4885RIPK2 274/4885ESR1 3891/4885 |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | CD274, PDCD1LG2, PDCD1 | XIAP 2368/4885RIPK2 2896/4885ESR1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.